Oncology

Compugen announced updated data surrounding the investigational therapeutic antibody, COM701, as monotherapy and in combination with nivolumab.

A novel imaging technology was cleared by the FDA to detect polyps with neoplastic potential during conduct of colonoscopy that aligns with pathological assessment with greater than 90% predictive ability.

Recently reported results from the ongoing phase 1 TUNINTIL trial of the oncolytic virus TILT-123 show safety of this approach.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, and urothelial cancer.

ONCOLOGY co–Editor-in-Chief Julie M. Vose, MD, MBA, details how underrepresentation of racial and ethnic minorities in clinical trials negatively impacts the medical community and calls for greater inclusion by removing some barriers to participation.

CancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.

Indications for pembrolizumab, nivolumab, and atezolizumab are set for examination under the FDA’s Oncologic Drugs Advisory Committee for indications granted accelerated approval in breast, urothelial, gastric, and liver cancers.

The liquid biopsy assay RaDaR has been given a breakthrough device designation for use in the detection of minimal residual disease in early-stage cancers.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about prostate cancer, breast cancer, lung cancer, and more.

Schilsky joined CancerNetwork®’s podcast to discuss ASCO’s Advance of the Year, the top priorities moving forward, and the COVID-19 pandemic.

Giorgio Trinchieri, MD, of the National Cancer Institute’s Center for Cancer Research joined CancerNetwork® to discuss enhancing the gut microbiome by way of fecal transplant for better immunotherapy responses.

The medical oncologist and physician scientist based at the University of Texas MD Anderson Cancer Center explained recommendations for SARS-CoV-2 vaccination in patients participating in phase 1 oncology clinical trials.

Investigators suggest that results of a study may help to identify concerns of individuals undergoing panel testing and ways to support their needs.

The chief of urologic oncology at City of Hope spoke about how the COVID-19 pandemic has altered the way he cares for patients with cancer as well as how he believes it will continue to impact cancer prevention, detection, and treatment moving forward.

A cancer care expert from The Ohio State University Comprehensive Cancer Hospital talks about what patients and their providers need to know about the COVID-19 vaccine.

With an estimated 2.3 million new cases identified, the Global Cancer Statistics 2020 report indicated female breast cancer was the most commonly diagnosed cancer type.

CancerNetwork® spoke with the CEO of the Union for International Cancer Control to learn more about their efforts in oncology amidst the COVID-19 pandemic, and the work they are doing on World Cancer Day.

CancerNetwork® reviews the biggest news on initiatives and advancements in cancer care on World Cancer Day.

The urologist at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center spoke about the impact of a decline in cancer screening tests being performed during the first wave of the pandemic.

Bellicum Pharmaceuticals, the developer of BPX-601, can now begin enrolling patients to their phase 1/2 trial again without modification to the study protocol.

The phase 3 RATIONALE 302 trial demonstrated that compared to chemotherapy, tislelizumab showed a statistically significant and clinically meaningful improvement in overall survival in the intention-to-treat population of patients with advanced or metastatic esophageal squamous cell carcinoma.

The increasing use of checkpoint inhibitors and other immunotherapies has created a need for the development of a cohesive education program and list of guidelines for treating common toxicities.

The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy.

Though the majority of immune-related adverse events (irAEs) can be managed with corticosteroids and other immunosuppressive treatments, life-threatening and sometimes fatal events have still been reported thus revealing a need to develop measures for effective management.

Merus announced that their bispecific antibody was granted fast track designation by the FDA for treating NRG1 fusion–positive solid tumors.